To #1 "based on current performance and fundaments.... the revenues are shrinking and the gross margins are abysmal for a generics company" About to turn around with all of that, and I may add that this is a plan that took place years ago by none other than Nasrat Hakim.
Revenues about to upstage with recent approvals of Percocet and Norco. All it takes is a foot in the door. Methadone will start them off slowly for this coming quarter. The following quarter should be interesting.
To #2 "Past performance, did management do what they said they were going to do? in this case, of course it is another failing grade" Past performance is exactly that, past performance. And they did do exactly what they said they were going to do. Notice each basket NH mentioned filling one at a time? And about SequestOx, we just have to see what it will entail thanks in large part to the FDA.
To #3 "Future potential, Nasdaq stocks with no revenues are often mentioned but what is not understood is that these stocks are viewed to have POTENTIAL- again another failing grade for elite "
Say what? Elite no future potential? According to who? Isradipine, already being made, FDA cannot stop them there. SunGen/Elite ANDAs, I doubt the FDA can stop Elite there either. Approvals are coming and a manufacturing/marketing sales base is already in place whether it be
Glenmark or SunGen or another like Tagi. I give NH high marks on all fronts. His plan is finally coming together and all people have to do is buy buy buy, accumulate and hold until a buyout that will not be for a while.
By then Elite will be a force to be reckoned with. Strong pipeline with many generics and a wide assortment of delivery/manufacturing technologies for the buying pharmaceutical.
The facility where I work makes injectable drugs. Want to guess how much money it is pulling down? Not hundreds of millions..... try billions.
Solid dosage in many cases is much easier. So there is close to 1 billion shares outstanding and if Elite even comes close to that in revenue just divide the revenue by the shares outstanding and multiply by 20. Conservative, very conservative for a company likey to have the first line of true ADF prescription opioids.
